Stay updated with breaking news from Absci. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Absci (NASDAQ:ABSI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company’s Creation(TM) Platform involved in […]
Absci (NASDAQ:ABSI – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Absci to related companies based on the strength of its earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability. Profitability This table compares Absci and its […]
Absci (NASDAQ:ABSI – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Absci to similar businesses based on the strength of its profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Earnings & Valuation This table compares Absci […]
Zacks Investment Research downgraded shares of Absci (NASDAQ:ABSI – Get Rating) from a hold rating to a sell rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, “Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company’s Creation(TM) Platform […]
Absci Co. (NASDAQ:ABSI – Get Rating) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,890,000 shares, a growth of 35.4% from the March 15th total of 4,350,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover […]